Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$7 Mln
P/E Ratio
--
P/B Ratio
1.71
Industry P/E
--
Debt to Equity
1.11
ROE
-3.85 %
ROCE
-181.71 %
Div. Yield
0 %
Book Value
0
EPS
-0
CFO
$-117.86 Mln
EBITDA
$-81.87 Mln
Net Profit
$-80.45 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Biofrontera Inc (BFRI)
| -22.02 | -8.17 | -20.56 | -53.26 | -78.37 | -- | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Biofrontera Inc (BFRI)
| -60.35 | -84.89 | -87.81 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 59.17 | 11,278.97 | 26.62 | 8.05 | |
| 62.24 | 6,815.49 | 52.52 | 23.56 | |
| 58.21 | 11,313.41 | 389.73 | 0.76 | |
| 7.56 | 8,821.37 | -- | -3.24 |
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses,... which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts. Address: 120 Presidential Way, Woburn, MA, United States, 01801 Read more
CEO, President & Executive Chairman
Dr. Hermann Luebbert Ph.D.
CEO, President & Executive Chairman
Dr. Hermann Luebbert Ph.D.
Headquarters
Woburn, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Biofrontera Inc (BFRI) stood at $ 22 Mln as on 31-Dec-24
The share price of Biofrontera Inc (BFRI) is $0.85 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Biofrontera Inc (BFRI) has given a return of -78.37% in the last 3 years.
Biofrontera Inc (BFRI) has a market capitalisation of $ 7 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Biofrontera Inc (BFRI) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Biofrontera Inc (BFRI) and enter the required number of quantities and click on buy to purchase the shares of Biofrontera Inc (BFRI).
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts. Address: 120 Presidential Way, Woburn, MA, United States, 01801
The CEO & director of Dr. Hermann Luebbert Ph.D.. is Biofrontera Inc (BFRI), and CFO & Sr. VP is Dr. Hermann Luebbert Ph.D..
There is no promoter pledging in Biofrontera Inc (BFRI).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,131
|
|
|
1,128
|
|
|
882
|
|
|
682
|
| Biofrontera Inc (BFRI) | Ratios |
|---|---|
|
Return on equity(%)
|
-384.98
|
|
Operating margin(%)
|
-41.9
|
|
Net Margin(%)
|
-47.61
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Biofrontera Inc (BFRI) was $0 Mln.
$0.02
(
